Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp

Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can arise due to several host or tumor-related factors. However, most current...

Descripción completa

Detalles Bibliográficos
Autores principales: Alfarouk, Khalid O, Stock, Christian-Martin, Taylor, Sophie, Walsh, Megan, Muddathir, Abdel Khalig, Verduzco, Daniel, Bashir, Adil H H, Mohammed, Osama Y, Elhassan, Gamal O, Harguindey, Salvador, Reshkin, Stephan J, Ibrahim, Muntaser E, Rauch, Cyril
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502609/
https://www.ncbi.nlm.nih.gov/pubmed/26180516
http://dx.doi.org/10.1186/s12935-015-0221-1
_version_ 1782381236877000704
author Alfarouk, Khalid O
Stock, Christian-Martin
Taylor, Sophie
Walsh, Megan
Muddathir, Abdel Khalig
Verduzco, Daniel
Bashir, Adil H H
Mohammed, Osama Y
Elhassan, Gamal O
Harguindey, Salvador
Reshkin, Stephan J
Ibrahim, Muntaser E
Rauch, Cyril
author_facet Alfarouk, Khalid O
Stock, Christian-Martin
Taylor, Sophie
Walsh, Megan
Muddathir, Abdel Khalig
Verduzco, Daniel
Bashir, Adil H H
Mohammed, Osama Y
Elhassan, Gamal O
Harguindey, Salvador
Reshkin, Stephan J
Ibrahim, Muntaser E
Rauch, Cyril
author_sort Alfarouk, Khalid O
collection PubMed
description Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can arise due to several host or tumor-related factors. However, most current research is focused on tumor-specific factors and specifically genes that handle expression of pumps that efflux accumulated drugs inside malignantly transformed types of cells. In this work, we suggest a wider and alternative perspective that sets the stage for a future platform in modifying drug resistance with respect to the treatment of cancer.
format Online
Article
Text
id pubmed-4502609
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45026092015-07-16 Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp Alfarouk, Khalid O Stock, Christian-Martin Taylor, Sophie Walsh, Megan Muddathir, Abdel Khalig Verduzco, Daniel Bashir, Adil H H Mohammed, Osama Y Elhassan, Gamal O Harguindey, Salvador Reshkin, Stephan J Ibrahim, Muntaser E Rauch, Cyril Cancer Cell Int Review Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy. Chemotherapy resistance can arise due to several host or tumor-related factors. However, most current research is focused on tumor-specific factors and specifically genes that handle expression of pumps that efflux accumulated drugs inside malignantly transformed types of cells. In this work, we suggest a wider and alternative perspective that sets the stage for a future platform in modifying drug resistance with respect to the treatment of cancer. BioMed Central 2015-07-15 /pmc/articles/PMC4502609/ /pubmed/26180516 http://dx.doi.org/10.1186/s12935-015-0221-1 Text en © Alfarouk et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Alfarouk, Khalid O
Stock, Christian-Martin
Taylor, Sophie
Walsh, Megan
Muddathir, Abdel Khalig
Verduzco, Daniel
Bashir, Adil H H
Mohammed, Osama Y
Elhassan, Gamal O
Harguindey, Salvador
Reshkin, Stephan J
Ibrahim, Muntaser E
Rauch, Cyril
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
title Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
title_full Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
title_fullStr Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
title_full_unstemmed Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
title_short Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
title_sort resistance to cancer chemotherapy: failure in drug response from adme to p-gp
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4502609/
https://www.ncbi.nlm.nih.gov/pubmed/26180516
http://dx.doi.org/10.1186/s12935-015-0221-1
work_keys_str_mv AT alfaroukkhalido resistancetocancerchemotherapyfailureindrugresponsefromadmetopgp
AT stockchristianmartin resistancetocancerchemotherapyfailureindrugresponsefromadmetopgp
AT taylorsophie resistancetocancerchemotherapyfailureindrugresponsefromadmetopgp
AT walshmegan resistancetocancerchemotherapyfailureindrugresponsefromadmetopgp
AT muddathirabdelkhalig resistancetocancerchemotherapyfailureindrugresponsefromadmetopgp
AT verduzcodaniel resistancetocancerchemotherapyfailureindrugresponsefromadmetopgp
AT bashiradilhh resistancetocancerchemotherapyfailureindrugresponsefromadmetopgp
AT mohammedosamay resistancetocancerchemotherapyfailureindrugresponsefromadmetopgp
AT elhassangamalo resistancetocancerchemotherapyfailureindrugresponsefromadmetopgp
AT harguindeysalvador resistancetocancerchemotherapyfailureindrugresponsefromadmetopgp
AT reshkinstephanj resistancetocancerchemotherapyfailureindrugresponsefromadmetopgp
AT ibrahimmuntasere resistancetocancerchemotherapyfailureindrugresponsefromadmetopgp
AT rauchcyril resistancetocancerchemotherapyfailureindrugresponsefromadmetopgp

Ejemplares similares